NVZMY
Novozymes A/S ADROTCPK - Current
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Thu, May 19, 11:48 AM
    • A Monsanto (MON +4.9%) takeover by Bayer is considered "relatively unlikely" by Jefferies analyst Laurence Alexander, as he expects MON to object to the offer given its conviction in its R&D pipeline and longer-term competitive advantages.
    • Alexander thinks shares of Syngenta (SYT -0.5%) and DuPont (DD -0.7%) could be pressured as regulatory scrutiny likely would intensify if MON gets acquired, and BASF (OTCQX:BASFY -1.4%) could fall on investor concerns of a potential counter-bid.
    • But the analyst sees a potential MON takeover as positive for shares of Novozymes (OTCPK:NVZMY -0.1%) and FMC Corp. (FMC -0.7%), as "a further roll-up of 'specialty generic' agrichemical assets could entice capital, and FMC would be a plausible anchor for such an attempt."
    • Jefferies rates MON as a Hold with a $95 price target.
    • Now read Bayer investor "deeply concerned" about move for Monsanto
    | Thu, May 19, 11:48 AM | 8 Comments
  • Tue, Apr. 12, 3:23 AM
    • Danske Bank downgrades Novozymes to Sell.
    • Price target is 270 Danish Krone. Implied downside 6%.
    • Novozymes -1.9% to 288 DKK.
    • Now read What If Gilead Goes Shopping?
    | Tue, Apr. 12, 3:23 AM | 1 Comment
  • Dec. 11, 2013, 10:29 AM
    • Monsanto (MON) is teaming up with a Danish biotech Novozymes (NVZMF, NVZMY) to develop microscopic organisms that help plants grow and resist pests, a move that could enable it to circumvent some concerns over its genetically modified seeds.
    • MON will pay $300M as part of the deal, in which the companies plan to combine their efforts to cultivate beneficial bacteria; they will split the cost of development equally and each get 50% of the profits from sales.
    • The idea of using microbes for plants hasn't caught on yet in part because many of the largest farmers are used to growing crops with synthetic fertilizer, scientists say.
    | Dec. 11, 2013, 10:29 AM | 1 Comment